Clinical significance of lymph node micrometastasis in stage I and II colon cancer.
OBJECTIVE
A 25% rate of recurrence after performing complete resection in node-negative colon cancer patients suggests that their nodal staging is frequently suboptimal. Moreover, the value of occult cancer cells in tumor-free lymph nodes still remains uncertain. The authors evaluated the prognostic significance of the pathologic parameters, including the lymph node occult disease (micrometastases) detected by immunohistochemistry, in patients with node-negative colon cancer.


METHODS
The study included 160 patients with curatively resected stage I or II colon cancer and they were without rectal cancer. 2852 lymph nodes were re-examined by re-do hematoxylin and eosin (H-E) staining and immunohistochemical staining. The detection rates were compared with the clinicopathologic characteristics and with the cancer-specific survival.


RESULTS
Occult metastases were detected in 8 patients (5%). However, no clinicopathologic parameter was found to be correlated with the presence of micrometastasis. Twenty patients developed recurrence at a median follow-up of 45.7 months: 14 died of colon cancer and 9 died from noncancer-related causes. Univariate analysis showed that lymphatic invasion and the number of retrieved lymph nodes significantly influenced survival, and multivariate analysis revealed that the stage, the number of retrieved lymph nodes and lymphatic invasion were independently related to the prognosis.


CONCLUSIONS
Inadequate lymph node retrieval and lymphatic invasion were found to be associated with a poorer outcome for node-negative colon cancer patients. The presence of immunostained tumors cells in pN0 lymph nodes was found to have no significant effect on survival, but these tumor were identified by re-do H-E staining. Maximal attention should be paid to the total number of lymph nodes that are retrieved during surgery for colon cancer patients.
Park
Sun Jin
SJ
Department of Surgery, Kyung Hee University College of Medicine, Seoul, Korea.
Lee
Kil Yeon
KY
Kim
Si Young
SY
Am J Clin Pathol. 1981 Mar;75(3):283-90
7010989
Int J Colorectal Dis. 2004 Sep;19(5):430-7
14716495
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
Ann Surg. 2006 Oct;244(4):602-10
16998369
Clin Cancer Res. 2002 Mar;8(3):759-67
11895906
Cancer. 1990 Feb 15;65(4):967-70
2297665
J Clin Oncol. 2002 Oct 15;20(20):4232-41
12377967
Ann Surg. 1971 Jan;173(1):44-6
5543548
Clin Cancer Res. 1999 Aug;5(8):2065-8
10473087
J Clin Oncol. 2002 Feb 15;20(4):1049-55
11844829
Oncology. 1999 Nov;57(4):276-80
10575311
Ann Surg. 2007 Oct;246(4):568-75; discussion 575-7
17893493
Eur J Surg. 1996 Aug;162(8):637-42
8891622
J Gastroenterol. 1997 Dec;32(6):758-64
9430013
Ann Surg Oncol. 1996 Mar;3(2):124-30
8646511
Dis Colon Rectum. 2002 Jun;45(6):750-5; discussion755-6
12072625
Dis Colon Rectum. 2004 Jul;47(7):1151-7
15164250
Ann Surg Oncol. 2000 Sep;7(8):601-8
11005559
Ann Surg Oncol. 2001 May;8(4):300-4
11352302
N Engl J Med. 1998 Jul 23;339(4):223-8
9673300
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Cancer. 1994 Feb 1;73(3):563-9
7507795
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
11309435